Pharmaceutical preparation for improving absorption and postprandial hypoglycemic action of insulin
AssigneeEli Lilly and Company
InventorsJean-Luc Ardilouze, Maude Gagnon-Auger, Fernand Gobeil, Julie Menard, Jean-Patrice Baillargeon, Pascal Brassard
Life of this patent
Estimating the term…
Abstract
The present disclosure relates to compositions and combinations comprising one or more insulin(s) and one or more vasoactive agent(s), and use thereof for increasing subcutaneous insulin absorption and/or treating diabetes and/or treating or preventing hyperglycemia or complications in a patient in need thereof.
Claims8
A method for treating diabetes comprising simultaneously administering subcutaneously to the same site in a subject in need thereof, a therapeutically effective amount of a short-acting insulin analog (SAIA) and a subcutaneously vasoactive effective amount of iloprost;
- wherein the ratio of SAIA to iloprost is 10-30 U SAIA:
- about 1 nmol iloprost;
- wherein the vasoactive effective amount of iloprost causes a local increase of blood flow in subcutaneous adipose tissue.
Dependencies are inferred from the claim text.